Indivior Pharmaceuticals, Inc. - 10-Q Filing
Indivior Pharmaceuticals reports Q3 2026 results including updates on Supernus Pharmaceuticals acquisition and ongoing opioid litigation.
Tickers: $INDV
Read the full article at SEC EDGAR
Part of the story Phathom Pharmaceuticals, Inc. - 10-Q Filing (11 articles)